Enalaprilat, the active intravenous form of enalapril, is an angiotensin-converting enzyme (ACE) inhibitor used to treat hypertension and acute heart failure. It was developed in the late 1970s and early 1980s, following research into ACE inhibitors that could effectively lower blood pressure and improve cardiac function. Its history is notable for its effectiveness in rapidly reducing blood pressure and improving hemodynamics in hospitalized patients, particularly those unable to take oral medication. Enalaprilat is administered intravenously, allowing immediate therapeutic action, and its use is guided by careful monitoring of blood pressure and kidney function to prevent adverse effects such as hypotension or renal impairment. Its development also included expanded clinical trials that established dosing protocols and safety monitoring in acute care settings.
BRAND NAMES
Vasotec IV – commonly used brand name for the intravenous formulation.
Enap IV – another brand name used in some regions.
MECHANISM OF ACTION
The mechanism of action refers to the specific biochemical interaction through which a drug or substance produces its effect in the body. It involves the binding of the drug to a particular target, such as a receptor, enzyme, or protein, followed by activation or inhibition of that target. This interaction triggers a series of cellular and molecular changes that ultimately lead to a physiological response.
PHARMACOKINETICS
Absorption
It determines how quickly and how much of the drug reaches systemic circulation. This process can occur through various routes such as oral, intravenous, intramuscular, or topical administration.
Distribution
Volume of distribution is a theoretical parameter that describes how extensively a drug is distributed throughout the body relative to the concentration of the drug in the blood or plasma. It is defined as the ratio of the total amount of drug in the body to the concentration of the drug in the plasma.
Metabolism
Enalaprilat undergoes minimal metabolism in the body. It is actually the active metabolite of the prodrug Enalapril, which is converted to enalaprilat in the liver. Once formed, enalaprilat does not undergo significant further biotransformation.
Elimination
filtration (drug passes from blood into urine), secretion (active transport of drug into renal tubules), and reabsorption (movement of drug back into the bloodstream). The rate of elimination depends on factors such as kidney and liver function, blood flow, and the drug’s chemical properties.
PHARMACODYNAMICS
Pharmacodynamics describes how a drug produces its effects in the body by interacting with specific molecular targets, such as enzymes, receptors, or ion channels. It explains the relationship between the drug concentration at the site of action and the resulting physiological or therapeutic response.
ADMINISTRATION
Administration refers to the route and method by which a drug is given to a patient to achieve its desired therapeutic effect. The choice of administration affects the onset, intensity, and duration of the drug’s action. Common routes include oral, intravenous (IV), intramuscular (IM), subcutaneous (SC), topical, and inhalational.
DOSAGE AND STRENGTH
Dosage refers to the amount of a drug administered at one time or over a specific period, while strength indicates the concentration of the active drug in a formulation. Both are essential for achieving the desired therapeutic effect while minimizing side effects.
DRUG INTERACTIONS
Drug interactions occur when one medication affects the pharmacokinetics or pharmacodynamics of another, altering its therapeutic effect or increasing the risk of adverse effects. Factors include changes in absorption, metabolism, distribution, or excretion.
FOOD INTERACTIONS
Food interactions occur when the consumption of certain foods affects the absorption, metabolism, or effectiveness of a drug. For example, the presence of food in the stomach can slow gastric emptying and delay the absorption of some medications, while high-fat meals can increase absorption of lipid-soluble drugs.
CONTRAINDICATIONS
Enalapril is contraindicated in patients with a history of angioedema related to previous ACE inhibitor therapy, as it may trigger life-threatening swelling. It should not be used during pregnancy, particularly in the second and third trimesters, due to the risk of fetal injury or death.
SIDE EFFECTS
Cough – persistent dry cough is common.
Dizziness or lightheadedness – especially when standing .
Fatigue or weakness.
Headache.
Hypotension – low blood pressure, particularly after the first dose.
Hyperkalemia – elevated blood potassium levels.
Kidney dysfunction – increased creatinine or reduced kidney function.
Angioedema – swelling of face, lips, tongue, or throat.
Nausea or diarrhea – mild gastrointestinal symptoms.
TOXICITY
Toxicity refers to the harmful effects that occur when a drug is taken in excessive doses or accumulates in the body. For Enalapril, overdose or excessive exposure can lead to severe hypotension, marked hyperkalemia, and acute kidney injury. In rare cases, it may precipitate angioedema or electrolyte imbalances that can be life-threatening. Symptoms of enalapril toxicity include dizziness, fainting, palpitations, shortness of breath, and swelling of the face or throat.
